ARS Pharmaceuticals, Inc. SPRY Payments to Acquire Short-Term Investments
Payments to Acquire Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireShortTermInvestments.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s payments to acquire short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s payments to acquire short-term investments?
- ARS Pharmaceuticals, Inc. (SPRY) reported payments to acquire short-term investments of $14.71M in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s payments to acquire short-term investments changed year-over-year?
- ARS Pharmaceuticals, Inc.'s payments to acquire short-term investments decreased by 57.2% year-over-year, from $34.35M to $14.71M.